Human Papilloma Virus, Laryngeal Papilloma, Recurrent, Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis
Conditions
Keywords
Human Papilloma Virus (HPV), Monoclonal Antibody, PD-L1 Expression
Brief summary
Background: Programmed cell death protein 1 (PD-L1) is a protein on the surface of cells. It regulates if a cell can be killed by immune system cells. It is thought to be able to affect the immune system response to diseased cells like those infected with a virus. The molecule M7824 interferes with the activity of PD-L1. It could help the immune system kill cells infected with a virus . Since recurrent respiratory papillomatosis is caused by a virus infection, this molecule could help. Objective: To see if M7824 works in treating recurrent respiratory papillomatosis. Eligibility: Adults ages 18 years or older with recurrent respiratory papillomatosis Design: Participants will be screened with: Medical history Physical exam Blood and pregnancy tests Endoscopy procedure in clinic. A small tube with a camera will look at the inside of the nose, throat, larynx, and upper windpipe. Some participants will also be screened with a chest scan. At the start of the study, participants will: Have a sedated endoscopy procedure where biopsies will be taken. Have blood tests. Have apheresis. Blood will be collected by a tube in an arm vein. A machine will remove white blood cells. The rest of the blood will be returned into an arm vein. Fill out a voice questionnaire. Participants will get the study molecule into a vein over about 1 hour. They will get it every other week for up to 12 weeks. Participants will repeat screening and starting procedures throughout the study. They will also review side effects and any medicine they are taking. When they are done with the study treatment, participants will be evaluated by repeating the study procedures. They may be evaluated periodically until their disease progresses.
Detailed description
Background * Recurrent respiratory papillomatosis (RRP) is a rare papillomatous disease of the aerodigestive tract that is caused by the Human Papilloma Virus (HPV). * RRP can progress to cause airway compromise, fatal pulmonary lesions, and invasive cancers. * There is no effective systemic therapy for RRP. Patients typically require repeated interventional procedures for disease control. * A recently completed phase II clinical trial investigating avelumab in subjects with aggressive RRP demonstrated an acceptable safety profile from Avelumab and a high rate of partial responses. * RRP is characterized by frequent expression of PD-L1 and transforming growth factor beta (TGF)-beta in the tumor microenvironment. * This clinical trial will evaluate the activity of M7824, a novel bifunctional fusion protein composed of a fully human Immunoglobulin G1 (IgG1) monoclonal antibody against human PD-L1 (avelumab) fused, via a flexible glycine-serine linker, to the soluble extracellular domain of human TGF- B receptor II (Transforming growth factor, beta receptor II (TGF-BRII), which functions as a TGF-B trap. This drug was selected for its demonstrated activity in a variety of cancers and for its acceptable safety profile. Objective \- Determine the complete response rate for M7824 in the treatment of patients with RRP. Eligibility * Histologically confirmed diagnosis of RRP. * One of the following: * A Derkay anatomic score of 10 or greater and a history of two or more endoscopic interventions in the last 12 months for control of RRP. * Pulmonary RRP with pulmonary disease that is measurable by computed tomography scan. * Tracheal involvement with RRP that has required either two or more endoscopic interventions in the last 12 months or a tracheostomy. * Age 18 years or greater. * Eastern Oncology Cooperative Group Performance Score of 0 or 1. Design * This is a phase II clinical trial with two cohorts that will enroll simultaneously. * Cohort 1 will consist of subjects who have not been treated previously with an immune checkpoint inhibitor. Cohort 2 will consist of subjects whose disease has been treated previously with andrefractory to an immune checkpoint inhibitor. Each cohort will have a Simon optimal two-stage design with initial enrollment of 12 patients and expands 21 patients if one or more complete response(s) is/are observed in the initial patients. With amendment D, dated 7/24/2019, cohort 2 will be closed to further enrollment.
Interventions
DRUGM7824
Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Recurrent Respiratory Papillomatosis (RRP) criteria: * Histological diagnosis of RRP confirmed by pathology report from a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. * One of the following: * A Derkay anatomic score of 10 or greater and a history of two or more endoscopic interventions in the last 12 months for control of RRP. * Pulmonary RRP with pulmonary disease that is measurable by computed tomography scan and evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. * Tracheal involvement with RRP that has required either two or more endoscopic interventions in the last 12 months or a tracheostomy. * Greater than or equal to 18 years of age. * Able to understand and sign the Informed Consent Document. * Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1. * Willing to undergo endoscopic evaluation with biopsies in compliance with this protocol. * No systemic therapy for RRP for at least 3 half-lives of the prior drug(s). * Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to first dose: * White Blood Count (WBC) \> 2000/ microliter * Neutrophils \> 1000/ microliter * Platelets \> 75 x10(3)/ microliter * Hemoglobin \> 9.0 g/dL * Serum Creatinine \< 1.5 x upper limits of normal (ULN) OR estimated glomerular filtration rate (eGFR) \> 30 mL/min (measured or calculated using the Modification of Diet in Renal Disease (MDRD) equation). * Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) less than or equal to 2.5 x ULN * Total Bilirubin: 1.5 x ULN * Prothrombin time (PT)/International Normalized Ratio (INR) and partial thromboplastin time (PTT) less than or equal to ULN * Sexually active subjects (men and women) of reproductive potential must agree to use two methods of contraception: one highly effective and one other effective method throughout M7824 treatment and for at least 120 days after M7824 treatment. Highly Effective Methods are defined as: Intrauterine device (IUD), hormonal (birth control pills, injections, implants), tubal ligation and partner s vasectomy; Other are defined as: latex condom, diaphragm and cervical cap. * Seronegative for human immunodeficiency virus (HIV) antibody. The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment. * Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests (Hep B Deoxyribonucleic acid (DNA) Quant, hepatitis B virus (HBV) Viral Load), and if confirmatory tests are negative, the patient can be enrolled. * Seronegative for hepatitis C antibody unless antigen negative. If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by Hep C Ribonucleic acid (RNA) Quant, hepatitis C virus (HCV) Viral Load and be HCV RNA negative.
Exclusion criteria
* Any severe acute or chronic medical or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, liver disease, lung disease (with the exception of what is specified in inclusion criteria) , or laboratory abnormalities that, in the opinion of the investigators, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results and in the judgment of the investigator, would make the patient inappropriate for entry into this study. Patients with mild to moderate asthma or chronic obstructive pulmonary disease (COPD) well controlled with oral or inhaled medications are permitted to enroll. * Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, or psoriasis not requiring systemic treatment, are permitted to enroll. * Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled, topical intranasal or intro-ocular steroids, and adrenal replacement doses \<10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. * Prior organ transplantation, including allogeneic stem cell transplantation. * Patients who are receiving any other investigational agents * Pregnant or breast feeding. Women of childbearing potential must have a negative pregnancy test at screening. Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post-menopause is defined as amenorrhea greater than or equal to 12 consecutive months. Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti- estrogens, ovarian suppression or any other reversible reason. * History of allergy to study drug components. * History of severe hypersensitivity reaction to any monoclonal antibody (Grade greater than or equal to 3 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v 5.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma). * Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (greater than or equal to New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. * Persisting toxicity related to prior therapy of Grade \>1 NCI-CTCAE v 5.0; however, alopecia, sensory neuropathy Grade less than or equal to 2 or other Grade less than or equal to 2 adverse events (AEs) not constituting a safety risk based on investigator's judgment are acceptable. * Known alcohol or drug abuse. * Vaccination within 4 weeks of the first dose of M7824 and 4 weeks after the last dose of M7824 are prohibited. * Human papillomavirus (HPV) vaccination within one year of the first dose of M7824 * With amendment D, patients that received prior Programmed cell death protein 1 (PD-1) based immunotherapy will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With a Complete Response | Response was assessed by flexible endoscopy with or without imaging studies before treatment and 6 and 12 weeks after starting treatment. | Complete response for M7824 in the treatment of patients with RRP was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is defined as no evidence of papillomas on physical exam and/or clinic-based flexible nasopharyngolaryngoscopy and/or tracheoscopy or by exam under anesthesia (sedation or general anesthesia) with endoscopy and biopsies, and absence of disease by imaging if lesions are assessed by imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With a Partial Response | Response was assessed by flexible endoscopy with or without imaging studies before treatment and 6 and 12 weeks after starting treatment. | Partial response for M7824 in the treatment of patients with RRP was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response is defined as a decrease in Derkay anatomic score of 30 percent or greater, and a partial tumor response by imaging using RECIST 1.1 criteria. |
| Number of Participants With ≥Grade 3 Adverse Events | Per protocol, adverse events are documented from the first administration of the study therapy, Study Day 1, through 42 days after the study therapy was last administered, up to 24 weeks + 42 days. | Adverse Events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is defined as severe or medically significant but not immediately life-threatening. Grade 4 is defined as life-threatening consequences; urgent intervention indicated. |
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | Per protocol, adverse events are documented from the first administration of the study therapy, Study Day 1, through 42 days after the study therapy was last administered, up to 24 weeks + 42 days. | Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 - Checkpoint Inhibitor Naive Patients Patients with Recurrent Respiratory Papillomatosis (RRP) who are checkpoint inhibitor naïve will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week. | 7 |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition Patients with Recurrent Respiratory Papillomatosis (RRP) who are refractory to checkpoint inhibition will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week. | 2 |
| Total | 9 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 0 | 1 |
Baseline characteristics
| Characteristic | Cohort 1 - Checkpoint Inhibitor Naive Patients | Total | Cohort 2 - Patients Refractory to Checkpoint Inhibition |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 1 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants | 8 Participants | 1 Participants |
| Age, Continuous | 32.42 years STANDARD_DEVIATION 13.04 | 39.79 years STANDARD_DEVIATION 14.68 | 47.17 years STANDARD_DEVIATION 16.32 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 8 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Median Baseline Derkay Score | 13 scores on a scale | 13 scores on a scale | 13.5 scores on a scale |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 6 Participants | 1 Participants |
| Region of Enrollment United States | 7 participants | 9 participants | 2 participants |
| Sex: Female, Male Female | 3 Participants | 4 Participants | 1 Participants |
| Sex: Female, Male Male | 4 Participants | 5 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 1 / 2 |
| other Total, other adverse events | 7 / 7 | 2 / 2 |
| serious Total, serious adverse events | 3 / 7 | 2 / 2 |
Outcome results
Primary
Proportion of Participants With a Complete Response
Complete response for M7824 in the treatment of patients with RRP was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is defined as no evidence of papillomas on physical exam and/or clinic-based flexible nasopharyngolaryngoscopy and/or tracheoscopy or by exam under anesthesia (sedation or general anesthesia) with endoscopy and biopsies, and absence of disease by imaging if lesions are assessed by imaging.
Time frame: Response was assessed by flexible endoscopy with or without imaging studies before treatment and 6 and 12 weeks after starting treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Proportion of Participants With a Complete Response | 0 proportion of participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Proportion of Participants With a Complete Response | 0 proportion of participants |
Secondary
Number of Participants With a Partial Response
Partial response for M7824 in the treatment of patients with RRP was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response is defined as a decrease in Derkay anatomic score of 30 percent or greater, and a partial tumor response by imaging using RECIST 1.1 criteria.
Time frame: Response was assessed by flexible endoscopy with or without imaging studies before treatment and 6 and 12 weeks after starting treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With a Partial Response | 1 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With a Partial Response | 0 Participants |
Secondary
Number of Participants With ≥Grade 3 Adverse Events
Adverse Events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is defined as severe or medically significant but not immediately life-threatening. Grade 4 is defined as life-threatening consequences; urgent intervention indicated.
Time frame: Per protocol, adverse events are documented from the first administration of the study therapy, Study Day 1, through 42 days after the study therapy was last administered, up to 24 weeks + 42 days.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Dyspnea | 1 Participants |
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Hypertension | 1 Participants |
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Laryngeal obstruction | 4 Participants |
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Lung infection | 1 Participants |
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Pain | 1 Participants |
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Sore throat | 1 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Pain | 0 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Dyspnea | 0 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Lung infection | 0 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Hypertension | 1 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Sore throat | 1 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With ≥Grade 3 Adverse Events | Grade 3 Laryngeal obstruction | 1 Participants |
Secondary
Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Per protocol, adverse events are documented from the first administration of the study therapy, Study Day 1, through 42 days after the study therapy was last administered, up to 24 weeks + 42 days.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 - Checkpoint Inhibitor Naive Patients | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 7 Participants |
| Cohort 2 - Patients Refractory to Checkpoint Inhibition | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 2 Participants |